9:41a ET 8/4/2022 - Benzinga
| Mentioned: | ADAP |
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.
Revenue was up $2.44 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
QuarterQ1 2022Q4 2021Q3 2021Q2 2021
EPS Estimate-0.220.14-0.26-0.24
EPS Actual-0.05-0.04-0.30-0.24
Revenue Estimate3.29M96.45M1.37M1.36M
Revenue Actual3.58M1.42M1.20M3.10M
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
No comments:
Post a Comment